Acumen Pharmaceuticals (NASDAQ:ABOS) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
Earnings & Valuation
This table compares Acumen Pharmaceuticals and Exelixis’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Acumen Pharmaceuticals||$1.44 million||414.80||N/A||N/A||N/A|
|Exelixis||$987.54 million||6.32||$111.78 million||$0.35||56.63|
Institutional and Insider Ownership
83.8% of Exelixis shares are owned by institutional investors. 3.3% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Acumen Pharmaceuticals and Exelixis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Acumen Pharmaceuticals and Exelixis, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Acumen Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 69.38%. Exelixis has a consensus price target of $34.67, suggesting a potential upside of 74.91%. Given Exelixis’ stronger consensus rating and higher probable upside, analysts plainly believe Exelixis is more favorable than Acumen Pharmaceuticals.
Exelixis beats Acumen Pharmaceuticals on 9 of the 10 factors compared between the two stocks.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.